Adiso Therapeutics Announces the Completion of a Phase 1b Multiple Ascending Dose Study of ADS051 for the Treatment of Moderately-to-Severely Active Ulcerative Colitis

Study demonstrated promising results; planning underway to initiate Phase 2 trial in 2H 2023 CONCORD, Mass., May 31, 2023 /PRNewswire/ — Adiso Therapeutics, Inc., a clinical-stage biotechnology company developing novel medicines targeting chronic inflammatory diseases today announced the completion of a Phase 1b multiple ascending dose (MAD) clinical trial evaluating ADS051 (BT051) an oral, gut-restricted, … Read more